Perrigo Company plc Income (Loss) from Continuing Operations, Per Basic Share
Perrigo Company plc (PRGO) reported Income (Loss) from Continuing Operations, Per Basic Share of $0.64 per share for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-08-05
- Perrigo Company plc income (loss) from continuing operations, per basic share for the quarter ending 2026-06-27 was $0.64.
- Perrigo Company plc income (loss) from continuing operations, per basic share for the quarter ending 2026-03-28 was -$2.81.
- Perrigo Company plc income (loss) from continuing operations, per basic share for the quarter ending 2025-09-27 was $0.09.
- Perrigo Company plc income (loss) from continuing operations, per basic share for the quarter ending 2025-06-28 was $0.00.
- Perrigo Company plc income (loss) from continuing operations, per basic share for fiscal 2025 was -$10.12.
- Perrigo Company plc income (loss) from continuing operations, per basic share for fiscal 2024 was -$1.17.
- Perrigo Company plc income (loss) from continuing operations, per basic share for fiscal 2023 was -$0.03.
- Perrigo Company plc income (loss) from continuing operations, per basic share for fiscal 2022 was -$0.97.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2026-06-27 | $0.64 10-Q · filed 2026-08-05 | -$2.17 10-Q · filed 2026-08-05 | ||
| 2026-03-28 | -$2.81 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$10.12 10-K · filed 2026-02-26 | |||
| 2025-09-27 | $0.09 10-Q · filed 2025-11-05 | $0.09 10-Q · filed 2025-11-05 | ||
| 2025-06-28 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-03-29 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$1.17 10-K · filed 2026-02-26 | |||
| 2024-09-28 | -$0.13 10-Q · filed 2025-11-05 | -$0.87 10-Q · filed 2025-11-05 | ||
| 2024-06-29 | -$0.77 10-Q · filed 2025-08-06 | -$0.74 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | $0.03 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$0.03 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $0.11 10-Q · filed 2024-11-06 | $0.17 10-Q · filed 2024-11-06 | ||
| 2023-07-01 | $0.07 10-Q · filed 2024-08-02 | $0.06 10-Q · filed 2024-08-02 | ||
| 2023-04-01 | -$0.01 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$0.97 10-K · filed 2025-02-28 | |||
| 2022-10-01 | -$0.39 10-Q · filed 2023-11-07 | -$0.88 10-Q · filed 2023-11-07 | ||
| 2022-07-02 | -$0.48 10-Q · filed 2023-08-08 | -$0.49 10-Q · filed 2023-08-08 | ||
| 2022-04-02 | -$0.01 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$0.98 10-K · filed 2024-02-27 | |||
| 2021-10-02 | -$0.40 10-Q · filed 2022-11-08 | -$1.22 10-Q · filed 2022-11-08 | ||
| 2021-07-03 | -$0.84 10-Q · filed 2022-08-09 | -$0.82 10-Q · filed 2022-08-09 | ||
| 2021-04-03 | $0.02 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $0.32 10-K · filed 2023-02-28 | |||
| 2020-09-26 | $0.19 10-Q · filed 2021-11-12 | $0.71 10-Q · filed 2021-11-12 | ||
| 2020-06-27 | $0.09 10-Q · filed 2021-08-11 | $0.52 10-Q · filed 2021-08-11 | ||
| 2020-03-28 | $0.42 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.16 10-K · filed 2022-03-01 | |||
| 2014-06-28 | $1.78 10-K · filed 2014-08-14 | |||
| 2013-06-29 | $4.71 10-K · filed 2014-08-14 | |||
| 2012-06-30 | $4.22 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |